Summary & Overview
CPT 81378: High-Resolution HLA Class I and II Molecular Typing
CPT code 81378 denotes a high-resolution molecular laboratory assay for human leukocyte antigen (HLA) genes, covering HLA Class I (A, B, C) and Class II (DRB1). This detailed genotyping is clinically important for transplant matching, immunogenetics, and certain diagnostic contexts where precise HLA characterization affects clinical decisions. Nationally, accurate HLA typing supports organ and stem cell transplantation programs and informs precision immunology care pathways.
Key payers addressed in this summary include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical scope, typical service setting, and what to expect in payer coverage discussions. The publication outlines common billing and documentation themes relevant to molecular laboratory services, highlights benchmarking topics used by payers, and summarizes policy and reimbursement considerations that commonly affect HLA molecular testing nationwide.
This resource is intended to orient laboratory managers, billing professionals, and policy analysts to the clinical context, payer landscape, and operational considerations tied to CPT code 81378, enabling informed engagement with payers and institutional stakeholders about HLA high-resolution testing.
Billing Code Overview
CPT code 81378 describes a high-resolution molecular laboratory test that assesses human leukocyte antigen (HLA) genes for Classes I and II. For this service, HLA Class I includes HLA–A, HLA–B, and HLA–C, and HLA Class II for this test includes HLA–DRB1.
Service type: Technical molecular laboratory testing for high-resolution HLA typing.
Typical site of service: Clinical diagnostic laboratory or reference molecular laboratory.
Clinical & Coding Specifications
Clinical Context
A patient being evaluated for organ transplantation compatibility or for investigation of suspected immune-mediated disease is referred for high-resolution HLA typing. Typical patients include potential kidney, liver, pancreas, or bone marrow transplant recipients and donors, and patients undergoing workup for recurrent pregnancy loss or suspected antibody‑mediated disease. The clinical workflow begins with collection of a peripheral blood specimen (EDTA tube) from the patient or donor in an outpatient clinic, transplant center, or hospital. The specimen is sent to a molecular diagnostics laboratory where DNA is extracted and amplified. The lab analyst performs high-resolution assessment of HLA Class I loci (HLA‑A, HLA‑B, HLA‑C) and HLA Class II locus (HLA‑DRB1) using sequence‑based typing or next‑generation sequencing methods. Results are reported as allelic-level HLA types used by transplant teams, histocompatibility labs, and immunology clinics to determine donor‑recipient compatibility, sensitization risk, and to guide immunosuppressive planning. Typical site of service: outpatient clinic, hospital inpatient, or independent molecular diagnostics laboratory performing technical testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When reporting the physician or laboratory director interpretation/analysis separate from the technical testing if applicable |